29.46  0.74 (2.58%)		06-12 16:00
Open: 28.64 High: 30.2302 Volume: 1,141,117		Pre. Close: 28.72 Low: 28.51 Market Cap: 1,752(M)

Short term
Mid term
Targets	6-month :	35.65	1-year :	41.64
Resists	First :	30.53	Second :	35.65
Pivot price	28.45
Supports	First :	28	Second :	26.44
MAs	MA(5) :	28.52	MA(20) :	28.41
	MA(100) :	28.89	MA(250) :	32.86
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	63	D(3) :	52.4
RSI	RSI(14): 55
52-week	High :	46	Low :	22.23

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AGIO ] has closed below upper band by 21.9%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	30.25 - 30.4	30.4 - 30.53
Low:	28.15 - 28.31	28.31 - 28.46
Close:	29.19 - 29.45	29.45 - 29.69

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Sun, 14 Jun 2026
Agios Pharmaceuticals (AGIO) Reports Promising Results from Phas - GuruFocus

Sat, 13 Jun 2026
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss - TradingView

Sat, 13 Jun 2026
AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion - TradingView

Sat, 13 Jun 2026
Sickle cell patients needed fewer transfusions with Agios pill in Phase 3 - Stock Titan

Tue, 09 Jun 2026
Analysts’ Top Healthcare Picks: McKesson (MCK), Agios Pharma (AGIO) - The Globe and Mail

Sat, 06 Jun 2026
Why Agios Pharmaceuticals (AGIO) Is Down 5.4% After Overhauling Its Hematology Portfolio - And What's Next - Sahm

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	59 (M)
Shares Float	53 (M)
Held by Insiders	1 (%)
Held by Institutions	108.6 (%)
Shares Short	7,450 (K)
Shares Short P.Month	7,080 (K)

EPS	-7.27
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	18.69
Profit Margin	0 %
Operating Margin	-530.4 %
Return on Assets (ttm)	-21.7 %
Return on Equity (ttm)	-32.9 %
Qtrly Rev. Growth	137.6 %
Gross Profit (p.s.)	-4.86
Sales Per Share	1.11
EBITDA (p.s.)	-7.91
Qtrly Earnings Growth	0 %
Operating Cash Flow	-380 (M)
Levered Free Cash Flow	-267 (M)

PE Ratio	-4.06
PEG Ratio	0
Price to Book value	1.57
Price to Sales	26.52
Price to Cash Flow	-4.61

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.